From the Research
Botropase is typically administered at a dosage of 1 ml (containing 1 KU of hemocoagulase) via intramuscular or intravenous injection, with frequency depending on the clinical situation, as supported by the most recent and highest quality study available 1.
Key Considerations
- The dosage may vary based on the specific clinical situation, patient's weight, age, and underlying conditions.
- For surgical procedures, it's often given before and after surgery to control bleeding.
- In cases of ongoing hemorrhage, the dose may be repeated every 4-6 hours as needed.
- For dental procedures, a single dose before treatment is usually sufficient.
- The maximum daily dose should not exceed 5 ml (5 KU).
Mechanism of Action
- Botropase works by accelerating blood clotting through two mechanisms: converting prothrombin to thrombin and fibrinogen to fibrin.
Safety and Side Effects
- This medication should be used cautiously in patients with hypercoagulable states or those on anticoagulant therapy.
- Side effects are rare but may include allergic reactions or hypotension.
Clinical Evidence
- A study published in 2012 compared the efficacy of batroxobin, tranexamic acid, and their combination in reducing blood loss and allogeneic blood transfusion in adolescent idiopathic scoliosis surgery, finding that the combination of batroxobin and tranexamic acid achieved the best results 1.
- Another study published in 2018 evaluated the effectiveness and safety of batroxobin, tranexamic acid, and their combination in reducing perioperative blood loss in lumbar spinal fusion surgery, finding that batroxobin and the combination of batroxobin with tranexamic acid significantly reduced perioperative blood loss compared to placebo 2.